Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21:551–60.
Article PubMed PubMed Central CAS Google Scholar
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
Article PubMed PubMed Central CAS Google Scholar
Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on Behalf of the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther. 2021;27:642–9.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
Article PubMed CAS Google Scholar
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401–7.
Article PubMed CAS Google Scholar
Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37:1277–84.
Article PubMed PubMed Central CAS Google Scholar
Naik S, Talleur AC, Li Y, Madden RM, Mamcarz E, Qudeimat A, et al. CD45RA-depleted haploidentical transplantation combined with NK cell addback results in promising long-term outcomes in pediatric patients with high-risk hematologic malignancies. Blood. 2021;138(Suppl 1):172.
Gabriel SS, Bon N, Chen J, Wekerle T, Bushell A, Fehr T, et al. Distinctive expression of Bcl-2 factors in regulatory T cells determines a pharmacological target to induce immunological tolerance. Front Immunol. 2016;7:73.
Article PubMed PubMed Central Google Scholar
Strobl J, Pandey RV, Krausgruber T, Kleissl L, Reininger B, Herac M, et al. Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. J Invest Dermatol. 2020;140:2188–98.
Article PubMed CAS Google Scholar
Davis JE, Du K, Ludford-Menting MJ, Prabahran A, Wong E, Huntington ND, et al. Venetoclax or ruxolitinib in pre-transplant conditioning lowers the engraftment barrier by different mechanisms in allogeneic stem cell transplant recipients. Front Immunol. 2021;12:749094.
留言 (0)